MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization application of Xervyteg® (MaaT013) in…
Categorie
HemOnc
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in…
June 2, 2025
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive results from Phase 3 trial…
May 13, 2025
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 Lyon, France, April…
April 28, 2025
Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Lyon, France, April 14, 2025 – 6.00pm CET – MaaT Pharma…
April 14, 2025
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT Following…
April 8, 2025
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co Lyon, France, April 7, 2025 –…
April 7, 2025
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies Lyon,…
March 31, 2025
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results Positive results from…
March 27, 2025
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host…
March 18, 2025
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.